InMed Merger Leaves Shareholders With Just 1.51% Stake, Legal Probe Underway
INM•INM shareholders in the proposed Mentari Therapeutics merger would hold only 1.51% of the combined company, raising concerns about unequal treatment. Legal firm Halper Sadeh LLC is investigating potential fiduciary breaches and may seek increased consideration on behalf of investors, working on a contingent fee basis.
1. Merger Terms
InMed Pharmaceuticals is set to merge with Mentari Therapeutics, after which INM shareholders are slated to own approximately 1.51% of the combined entity. This limited stake percentage has triggered questions about the fairness and relative value of the deal for existing investors.
2. Legal Investigation
Halper Sadeh LLC has launched an investigation into potential breaches of fiduciary duty and unfair deal structuring in the merger terms. The firm is offering to represent INM shareholders on a contingent fee basis, aiming to secure increased consideration or other relief without up-front costs.
3. Potential Impacts
Should the legal action succeed, shareholders could obtain higher per-share value or additional disclosures prior to closing. However, litigation may extend the merger timeline and introduce new deal terms, affecting INM’s near-term valuation and investor sentiment.
